Moreover, repression of TP53INP1 in human neuroblastoma tissues is a marker for poor patient prognosis, and BET bromodomain inhibitors reactivate TP53INP1 expression in cancer cells. This evidence concerns the gene TP53INP1 and neuroblastoma.